MedTrace Logo

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

NCT02006108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-05-11

Study results available
· View outcomes & findings →

Summary

The goal of this study is to develop a non-invasive imaging test for in vivo detection of kidney transplant rejection. The hypotheses are that 1) Ferumoxytol-MRI can generate accurate estimates of tissue iron concentrations and tissue macrophages. 2) The signal given by a renal allograft on Ferumoxytol-MRI demonstrates significant differences between rejected and non-rejected transplants.

Conditions

  • Renal Transplant Rejection

Interventions

DRUG

Feraheme

Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging

OTHER

MRI-GE Healthcare 3 Tesla magnet

All patients will undergo

Sponsors & Collaborators

Principal Investigators

  • Heike E Daldrup-Link, MD, PhD · Stanford University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-27
Primary Completion
2017-04-11
Completion
2017-04-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02006108 on ClinicalTrials.gov